[1] Sciuto R, Romano L, Rea S, et al. Natural history and clinical outcome of differentiated thyroid carcinoma:a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol, 2009, 20(10):1728-1735.
[2] Muresan MM, Olivier P, Leclere J, et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer, 2008, 15(1):37-49.
[3] Mihailovic JM, Stefanovic LJ, Malesevic MD, et al. Metastatic differentiated thyroid carcinoma:clinical management and outcome of disease in patients with initial and late distant metastases. Nucl Med Commun, 2009, 30(7):558-564.
[4] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma:benefits and limits of radioiodine therapy. J Clin Endocrinol Metab, 2006, 91(8):2892-2899.
[5] Schlumberger M, Tubiana M. De Vathaire F, et al. Long-term results of treatment of 283 patients with lung ang bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab, 1986, 63(4):960-967.
[6] Sugltani I, Fujimoto Y, Yamamoto N, et al. Papillary thyroid carcinoma with distant metastases:survival predictors and the importance of local control. Surgery, 2008, 143(1):35-42.
[7] Baitei EY, Zou M, A1-Mohanna F, et al. Aberrant BRAF splicingas an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J Pathol, 2009, 217(5):707-715.
[8] Kogai T, Sajid-Crockett S, Newmarch LS, et al. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid ceils and human papillary thyroid cancer cells. J Endocrinol, 2008, 199(2):243-252.
[9] Ahn SH, Henderson Y, Kang Y, et al. An orthotopic model of papillary thyroid carcinoma in athymic nude mice. Arch Otolaryngol Head Neck Surg, 2008, 134(2):190-197.
[10] Younes MN, Kim S, Yigitbasi OG, et al. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther, 2005, 4(8):1146-1156.
[11] Schweppe RE, Kerege AA, Sharma V, et al. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid, 2009, 19(8):825-835.
[12] Cheng SP, Yin PH, Chang YC, et al. Differential roles of leptin in regulating cell migration in thyroid cancer cells. Oncol Rep, 2010, 23(6):1721-1727.
[13] Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endoerinol Metab, 2008, 93(11):4331-4341.
[14] Klopper JP, Berenz A, Hays WR, et al. In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res, 2008, 14(2):589-596.
[15] Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther, 2007, 6(6):1785-1792.
[16] Nahari D, Satchi-Fainaro RS, Chen M, et al. Tumor cytotoxicity and endothelial Rac inhibition induced by TNP-470 in anaplastic thyroid cancer. Mol Cancer Ther, 2007, 6(4):1329-1337.
[17] Lin X, Zhu B, Liu Y, et al. Follicular thyroid carcinoma invades venous rather than lymphatic vessels. Diagn Pathol, 2010, 5:8.
[18] Hombaeh-Klonisch S, Bialek J, Radestock Y, et al. INSL3 has tumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3):521-531.
[19] Ereolino T, Lombardi A, Becherini L, et al. The Y606C RET mutation causes a receptor gain of function. Clin Endocrinol (Oxt), 2008, 69(2):253-258.
[20] Quidville V, Segond N, Tebbi A, et al. Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid, 2009, 19(6):613-621.
[21] Vitagliano D, De Falco V, Tamburrino A, et al. The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer, 2010, 18(1):1-11.
[22] Chen MC, Yu CH, Wang SW, et al. Anti-proliferative effects of evodiamine on human thyroid eancer cell line ARO. J Cell Biochem, 2010, 110(6):1495-1503.
[23] Arcinas A, Yen TY, Kebebew E, et al. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J Proteome Res, 2009, 8(8):3958-3968.
[24] Hoffmann S, Rockenstein A, Ramaswamy A, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol, 2007, 264(1-2):74-81.
[25] Fortin MA, Salnikov AV, Nestor M, et al. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36:application to antibody tumour uptake studies. Eur J Nucl Med Mol Imaging, 2007, 34(9):1376-1387.
[26] Leux C, Guénel P. Risk factors of thyroid tumors:role of environmental and occupational exposures to chemical pollutants. Rev Epidemiol Sante Publique, 2010, 58(5):359-367.
[27] Alfano RW, Leppla SH, Liu S, et al. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther, 2010, 9(1):190-201.
[28] Hombach-Klonisch S, Bialek J, Radestock Y, et al. INSL3 has tumorpromoting activity in thyroid cancer. Int J Cancer, 2010, 127(3):521-531.
[29] Zatelli MC, Tagliati F, Amodio V, et al. Role of pituitary tumour transforming gene 1 in medullary thyroid carcinoma. Anal Cell Pathol (Amst), 2010, 33(5):207-216.
[30] Henderson YC, Ahn SH, Kang Y, et al. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clin Cancer Res, 2008, 14(15):4908-4914.
[31] Nucera C, Nehs MA, Mekel M, et al. A novel orthotopic mouse model of human anaplastic thyroid carcinoma. Thyroid, 2009, 19(10):1077-1084.
[32] Sehiff BA, MeMurphy AB, Jasser SA, et al. Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res, 2004, 10(24):8594-8602.
[33] Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in athymic nude mice. Clin Cancer Res, 2005, 11(5):1713-1721.
[34] Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis:identification of S100 A4(Mtsl) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab, 2004, 89(12):6146-6154.